Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer
An Exploratory, Open-Label Phase I Pharmacodynamic Study of COX-2 Inhibition With Celecoxib (Celebrex) and Aromatase Activity in Breast Cancer
Status: Enrolling
Updated:  12/28/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Celecoxib in Treating Postmenopausal Women Who Are Undergoing Surgery for Invasive Breast Cancer
An Exploratory, Open-Label Phase I Pharmacodynamic Study of COX-2 Inhibition With Celecoxib (Celebrex) and Aromatase Activity in Breast Cancer
Status: Enrolling
Updated: 12/28/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase II Study of the Raf Kinase Inhibitor BAY43-9006 in Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated:  12/28/2016
North Central Cancer Treatment Group
mi
from
Rochester, MN
Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Phase II Study of the Raf Kinase Inhibitor BAY43-9006 in Patients With Advanced Non-Small Cell Lung Cancer
Status: Enrolling
Updated: 12/28/2016
North Central Cancer Treatment Group
mi
from
Rochester, MN
Click here to add this to my saved trials
Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors
A Phase I Genotype-Directed Dose-Escalation Study of Irinotecan (NSC616348, CPT-11, Camptosar) in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/3/2017
University of Chicago
mi
from
Chicago, IL
Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors
A Phase I Genotype-Directed Dose-Escalation Study of Irinotecan (NSC616348, CPT-11, Camptosar) in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/3/2017
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors
A Phase I Genotype-Directed Dose-Escalation Study of Irinotecan (NSC616348, CPT-11, Camptosar) in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  1/3/2017
NorthShore University HealthSystem
mi
from
Evanston, IL
Genotype-Directed Dose-Escalation Study of Irinotecan in Patients With Advanced Solid Tumors
A Phase I Genotype-Directed Dose-Escalation Study of Irinotecan (NSC616348, CPT-11, Camptosar) in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 1/3/2017
NorthShore University HealthSystem
mi
from
Evanston, IL
Click here to add this to my saved trials
Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
Status: Enrolling
Updated:  1/3/2017
HonorHealth Research Institute
mi
from
Scottsdale, AZ
Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
Status: Enrolling
Updated: 1/3/2017
HonorHealth Research Institute
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
Status: Enrolling
Updated:  1/3/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
Status: Enrolling
Updated: 1/3/2017
Cedars-Sinai Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
Status: Enrolling
Updated:  1/3/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
Status: Enrolling
Updated: 1/3/2017
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
Status: Enrolling
Updated:  1/3/2017
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
Status: Enrolling
Updated: 1/3/2017
Tennessee Oncology, PLLC
mi
from
Nashville, TN
Click here to add this to my saved trials
Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
Status: Enrolling
Updated:  1/3/2017
The Royal Marsden
mi
from
Sutton,
Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
A Phase I Dose Escalation Study of VS-5584, a Dual PI3K/mTOR Inhibitor, in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma
Status: Enrolling
Updated: 1/3/2017
The Royal Marsden
mi
from
Sutton,
Click here to add this to my saved trials
Immune Monitoring on Sipuleucel-T
A Systems Biology Approach to Immune Monitoring in Patients With Castration-resistant Prostate Cancer Receiving SiPuleucel-T
Status: Enrolling
Updated:  1/3/2017
Comprehensive Cancer Center of Nevada
mi
from
Las Vegas, NV
Immune Monitoring on Sipuleucel-T
A Systems Biology Approach to Immune Monitoring in Patients With Castration-resistant Prostate Cancer Receiving SiPuleucel-T
Status: Enrolling
Updated: 1/3/2017
Comprehensive Cancer Center of Nevada
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Immune Monitoring on Sipuleucel-T
A Systems Biology Approach to Immune Monitoring in Patients With Castration-resistant Prostate Cancer Receiving SiPuleucel-T
Status: Enrolling
Updated:  1/3/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Immune Monitoring on Sipuleucel-T
A Systems Biology Approach to Immune Monitoring in Patients With Castration-resistant Prostate Cancer Receiving SiPuleucel-T
Status: Enrolling
Updated: 1/3/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Immune Monitoring on Sipuleucel-T
A Systems Biology Approach to Immune Monitoring in Patients With Castration-resistant Prostate Cancer Receiving SiPuleucel-T
Status: Enrolling
Updated:  1/3/2017
Weill-Cornell Medical College
mi
from
New York, NY
Immune Monitoring on Sipuleucel-T
A Systems Biology Approach to Immune Monitoring in Patients With Castration-resistant Prostate Cancer Receiving SiPuleucel-T
Status: Enrolling
Updated: 1/3/2017
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated:  1/3/2017
Wichita NCORP
mi
from
Wichita, KA
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated: 1/3/2017
Wichita NCORP
mi
from
Wichita, KA
Click here to add this to my saved trials
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated:  1/3/2017
Cancer Research Consortium of West Michigan
mi
from
Grand Rapids, MI
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated: 1/3/2017
Cancer Research Consortium of West Michigan
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated:  1/3/2017
University of Rochester NCORP Research Base
mi
from
Rochester, NY
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated: 1/3/2017
University of Rochester NCORP Research Base
mi
from
Rochester, NY
Click here to add this to my saved trials
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated:  1/3/2017
Dayton NCORP
mi
from
Dayton, OH
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated: 1/3/2017
Dayton NCORP
mi
from
Dayton, OH
Click here to add this to my saved trials
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated:  1/3/2017
Greenville Health System NCORP
mi
from
Greenville, SC
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated: 1/3/2017
Greenville Health System NCORP
mi
from
Greenville, SC
Click here to add this to my saved trials
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated:  1/3/2017
Wisconsin NCORP
mi
from
Marshfield, WI
Omega-3 Fatty Acid in Reducing Cancer-Related Fatigue in Breast Cancer Survivors
Feasibility of Omega-3 Supplementation for Cancer-Related Fatigue
Status: Enrolling
Updated: 1/3/2017
Wisconsin NCORP
mi
from
Marshfield, WI
Click here to add this to my saved trials
Randomized Amifostine For SCCHN
Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Enrolling
Updated:  1/3/2017
Goodall Hospital
mi
from
Sanford, ME
Randomized Amifostine For SCCHN
Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Enrolling
Updated: 1/3/2017
Goodall Hospital
mi
from
Sanford, ME
Click here to add this to my saved trials
Randomized Amifostine For SCCHN
Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Enrolling
Updated:  1/3/2017
Massachusetts General Hospital
mi
from
Boston, MA
Randomized Amifostine For SCCHN
Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Enrolling
Updated: 1/3/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Randomized Amifostine For SCCHN
Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Enrolling
Updated:  1/3/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Randomized Amifostine For SCCHN
Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Enrolling
Updated: 1/3/2017
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Randomized Amifostine For SCCHN
Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Enrolling
Updated:  1/3/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Randomized Amifostine For SCCHN
Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Enrolling
Updated: 1/3/2017
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Randomized Amifostine For SCCHN
Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Enrolling
Updated:  1/3/2017
Bethke Cancer Center at Emerson Hospital
mi
from
Concord, MA
Randomized Amifostine For SCCHN
Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Enrolling
Updated: 1/3/2017
Bethke Cancer Center at Emerson Hospital
mi
from
Concord, MA
Click here to add this to my saved trials
Randomized Amifostine For SCCHN
Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Enrolling
Updated:  1/3/2017
Mass General/North Shore Cancer Center
mi
from
Danvers, MA
Randomized Amifostine For SCCHN
Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Enrolling
Updated: 1/3/2017
Mass General/North Shore Cancer Center
mi
from
Danvers, MA
Click here to add this to my saved trials
Randomized Amifostine For SCCHN
Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Enrolling
Updated:  1/3/2017
Saint Anne's Hospital - Fall River
mi
from
Fall River, MA
Randomized Amifostine For SCCHN
Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Enrolling
Updated: 1/3/2017
Saint Anne's Hospital - Fall River
mi
from
Fall River, MA
Click here to add this to my saved trials
Randomized Amifostine For SCCHN
Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Enrolling
Updated:  1/3/2017
Lowell General Hospital
mi
from
Lowell, MA
Randomized Amifostine For SCCHN
Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Enrolling
Updated: 1/3/2017
Lowell General Hospital
mi
from
Lowell, MA
Click here to add this to my saved trials
Randomized Amifostine For SCCHN
Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Enrolling
Updated:  1/3/2017
Wentworth-Douglass Hospital
mi
from
Dover, NH
Randomized Amifostine For SCCHN
Phase II, Randomized Study of Concomitant Chemoradiation Using Weekly Carboplatinum/Paclitaxel With (Arm A) or Without (Arm B) Daily Subcutaneous Amifostine in Patients With Newly Diagnosed Locally Advanced Squamous Cell Cancer of the Head and Neck
Status: Enrolling
Updated: 1/3/2017
Wentworth-Douglass Hospital
mi
from
Dover, NH
Click here to add this to my saved trials
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
A Phase II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Aplidin® as a 3-hour IV Infusion Every 2 Weeks, in Relapsing or Refractory Patients With Androgen-independent Prostate Adenocarcinoma..
Status: Enrolling
Updated:  1/3/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
A Phase II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Aplidin® as a 3-hour IV Infusion Every 2 Weeks, in Relapsing or Refractory Patients With Androgen-independent Prostate Adenocarcinoma..
Status: Enrolling
Updated: 1/3/2017
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
A Phase II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Aplidin® as a 3-hour IV Infusion Every 2 Weeks, in Relapsing or Refractory Patients With Androgen-independent Prostate Adenocarcinoma..
Status: Enrolling
Updated:  1/3/2017
Seattle Cancer Care Alliance
mi
from
Seattle, WA
A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer
A Phase II, Multicenter, Open-label, Clinical and Pharmacokinetic Study of Aplidin® as a 3-hour IV Infusion Every 2 Weeks, in Relapsing or Refractory Patients With Androgen-independent Prostate Adenocarcinoma..
Status: Enrolling
Updated: 1/3/2017
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
Exercise in Lessening Fatigue Caused by Cancer in Patients Undergoing Chemotherapy
A Study of the Effects of Exercise on Cancer-Related Fatigue
Status: Enrolling
Updated:  1/4/2017
James P. Wilmot Cancer Center at University of Rochester Medical Center
mi
from
Rochester, NY
Exercise in Lessening Fatigue Caused by Cancer in Patients Undergoing Chemotherapy
A Study of the Effects of Exercise on Cancer-Related Fatigue
Status: Enrolling
Updated: 1/4/2017
James P. Wilmot Cancer Center at University of Rochester Medical Center
mi
from
Rochester, NY
Click here to add this to my saved trials
Patient Outcomes of a Self-care Management Approach to Cancer Symptoms: A Clinical Trial
Status: Enrolling
Updated:  1/4/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Patient Outcomes of a Self-care Management Approach to Cancer Symptoms: A Clinical Trial
Status: Enrolling
Updated: 1/4/2017
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients
Randomized Phase I/II Pilot Study of the Immunogenicity of Cyclophosphamide With Peptide Pulsed Mature Dendritic Cells for Patients With Previously Treated Ovarian Epithelial or Primary Peritoneal Carcinoma
Status: Enrolling
Updated:  1/4/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Dendritic Cell Vaccine for High Risk Ovarian Cancer Patients
Randomized Phase I/II Pilot Study of the Immunogenicity of Cyclophosphamide With Peptide Pulsed Mature Dendritic Cells for Patients With Previously Treated Ovarian Epithelial or Primary Peritoneal Carcinoma
Status: Enrolling
Updated: 1/4/2017
Univ of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Patient Perception of Mammogram Guidelines
Patient Perception of Mammogram Guidelines
Status: Enrolling
Updated:  1/4/2017
UMassMemorial Medical Group- Auburn Gyn
mi
from
Auburn, MA
Patient Perception of Mammogram Guidelines
Patient Perception of Mammogram Guidelines
Status: Enrolling
Updated: 1/4/2017
UMassMemorial Medical Group- Auburn Gyn
mi
from
Auburn, MA
Click here to add this to my saved trials
Patient Perception of Mammogram Guidelines
Patient Perception of Mammogram Guidelines
Status: Enrolling
Updated:  1/4/2017
Shrewsbury Ob-Gyn
mi
from
Shrewsbury, MA
Patient Perception of Mammogram Guidelines
Patient Perception of Mammogram Guidelines
Status: Enrolling
Updated: 1/4/2017
Shrewsbury Ob-Gyn
mi
from
Shrewsbury, MA
Click here to add this to my saved trials
Patient Perception of Mammogram Guidelines
Patient Perception of Mammogram Guidelines
Status: Enrolling
Updated:  1/4/2017
UMassMemorial Medical Group- OB-GYN
mi
from
Shrewsbury, MA
Patient Perception of Mammogram Guidelines
Patient Perception of Mammogram Guidelines
Status: Enrolling
Updated: 1/4/2017
UMassMemorial Medical Group- OB-GYN
mi
from
Shrewsbury, MA
Click here to add this to my saved trials
Patient Perception of Mammogram Guidelines
Patient Perception of Mammogram Guidelines
Status: Enrolling
Updated:  1/4/2017
Women's Health of Central Mass
mi
from
Worcester, MA
Patient Perception of Mammogram Guidelines
Patient Perception of Mammogram Guidelines
Status: Enrolling
Updated: 1/4/2017
Women's Health of Central Mass
mi
from
Worcester, MA
Click here to add this to my saved trials
Creation of the BioBank, Early Detection and Discovery Biomarkers
Creation of the BioBank,To Establish a Multidisciplinary Research Structure That Facilitates Projects That Bridge Specialties That Normally May or May Not Interact.
Status: Enrolling
Updated:  1/5/2017
William Beaumont Hospitals
mi
from
Royal Oak, MI
Creation of the BioBank, Early Detection and Discovery Biomarkers
Creation of the BioBank,To Establish a Multidisciplinary Research Structure That Facilitates Projects That Bridge Specialties That Normally May or May Not Interact.
Status: Enrolling
Updated: 1/5/2017
William Beaumont Hospitals
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
Combined Fulvestrant and Anastrozole as Neo-adjuvant Endocrine Therapy in Postmenopausal Women With Hormone Receptor Positive Invasive Breast Cancer
Status: Enrolling
Updated:  1/5/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Anti-Hormone Therapy (With Anastrazole and Fulvestrant) Before Surgery to Treat Postmenopausal Women With Breast Cancer.
Combined Fulvestrant and Anastrozole as Neo-adjuvant Endocrine Therapy in Postmenopausal Women With Hormone Receptor Positive Invasive Breast Cancer
Status: Enrolling
Updated: 1/5/2017
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Music Therapy Video Development in Improving Communication, Emotional Distress, and Recovery in Adolescents/Young Adults Undergoing Treatment for High-Risk Cancer and Their Parents
Music Video for AYA-Parent Communication and Resilience
Status: Enrolling
Updated:  1/5/2017
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Music Therapy Video Development in Improving Communication, Emotional Distress, and Recovery in Adolescents/Young Adults Undergoing Treatment for High-Risk Cancer and Their Parents
Music Video for AYA-Parent Communication and Resilience
Status: Enrolling
Updated: 1/5/2017
Children's Healthcare of Atlanta - Egleston
mi
from
Atlanta, GA
Click here to add this to my saved trials
Music Therapy Video Development in Improving Communication, Emotional Distress, and Recovery in Adolescents/Young Adults Undergoing Treatment for High-Risk Cancer and Their Parents
Music Video for AYA-Parent Communication and Resilience
Status: Enrolling
Updated:  1/5/2017
Children's Healthcare of Atlanta @ Scottish Rite
mi
from
Atlanta, GA
Music Therapy Video Development in Improving Communication, Emotional Distress, and Recovery in Adolescents/Young Adults Undergoing Treatment for High-Risk Cancer and Their Parents
Music Video for AYA-Parent Communication and Resilience
Status: Enrolling
Updated: 1/5/2017
Children's Healthcare of Atlanta @ Scottish Rite
mi
from
Atlanta, GA
Click here to add this to my saved trials
Music Therapy Video Development in Improving Communication, Emotional Distress, and Recovery in Adolescents/Young Adults Undergoing Treatment for High-Risk Cancer and Their Parents
Music Video for AYA-Parent Communication and Resilience
Status: Enrolling
Updated:  1/5/2017
Riley Hospital for Children
mi
from
Indianapolis, IN
Music Therapy Video Development in Improving Communication, Emotional Distress, and Recovery in Adolescents/Young Adults Undergoing Treatment for High-Risk Cancer and Their Parents
Music Video for AYA-Parent Communication and Resilience
Status: Enrolling
Updated: 1/5/2017
Riley Hospital for Children
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Music Therapy Video Development in Improving Communication, Emotional Distress, and Recovery in Adolescents/Young Adults Undergoing Treatment for High-Risk Cancer and Their Parents
Music Video for AYA-Parent Communication and Resilience
Status: Enrolling
Updated:  1/5/2017
Children's Hospitals and Clinics of Minnesota - Minneapolis
mi
from
Minneapolis, MN
Music Therapy Video Development in Improving Communication, Emotional Distress, and Recovery in Adolescents/Young Adults Undergoing Treatment for High-Risk Cancer and Their Parents
Music Video for AYA-Parent Communication and Resilience
Status: Enrolling
Updated: 1/5/2017
Children's Hospitals and Clinics of Minnesota - Minneapolis
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Music Therapy Video Development in Improving Communication, Emotional Distress, and Recovery in Adolescents/Young Adults Undergoing Treatment for High-Risk Cancer and Their Parents
Music Video for AYA-Parent Communication and Resilience
Status: Enrolling
Updated:  1/5/2017
Children's Mercy Hospital
mi
from
Kansas City, MO
Music Therapy Video Development in Improving Communication, Emotional Distress, and Recovery in Adolescents/Young Adults Undergoing Treatment for High-Risk Cancer and Their Parents
Music Video for AYA-Parent Communication and Resilience
Status: Enrolling
Updated: 1/5/2017
Children's Mercy Hospital
mi
from
Kansas City, MO
Click here to add this to my saved trials
Music Therapy Video Development in Improving Communication, Emotional Distress, and Recovery in Adolescents/Young Adults Undergoing Treatment for High-Risk Cancer and Their Parents
Music Video for AYA-Parent Communication and Resilience
Status: Enrolling
Updated:  1/5/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Music Therapy Video Development in Improving Communication, Emotional Distress, and Recovery in Adolescents/Young Adults Undergoing Treatment for High-Risk Cancer and Their Parents
Music Video for AYA-Parent Communication and Resilience
Status: Enrolling
Updated: 1/5/2017
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Music Therapy Video Development in Improving Communication, Emotional Distress, and Recovery in Adolescents/Young Adults Undergoing Treatment for High-Risk Cancer and Their Parents
Music Video for AYA-Parent Communication and Resilience
Status: Enrolling
Updated:  1/5/2017
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Music Therapy Video Development in Improving Communication, Emotional Distress, and Recovery in Adolescents/Young Adults Undergoing Treatment for High-Risk Cancer and Their Parents
Music Video for AYA-Parent Communication and Resilience
Status: Enrolling
Updated: 1/5/2017
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy
Phase I/II Evaluation Magnetic Resonance Imaging (MRI)-Guided Differential-Dose Prostate Brachytherapy
Status: Enrolling
Updated:  1/5/2017
Saint Lukes-Roosevelt Hospital Center
mi
from
New York, NY
Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy
Phase I/II Evaluation Magnetic Resonance Imaging (MRI)-Guided Differential-Dose Prostate Brachytherapy
Status: Enrolling
Updated: 1/5/2017
Saint Lukes-Roosevelt Hospital Center
mi
from
New York, NY
Click here to add this to my saved trials
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated:  1/5/2017
Alaska Breast Care and Surgery LLC
mi
from
Anchorage, AK
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated: 1/5/2017
Alaska Breast Care and Surgery LLC
mi
from
Anchorage, AK
Click here to add this to my saved trials
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated:  1/5/2017
Alaska Women's Cancer Care
mi
from
Anchorage, AK
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated: 1/5/2017
Alaska Women's Cancer Care
mi
from
Anchorage, AK
Click here to add this to my saved trials
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated:  1/5/2017
Anchorage Oncology Centre
mi
from
Anchorage, AK
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated: 1/5/2017
Anchorage Oncology Centre
mi
from
Anchorage, AK
Click here to add this to my saved trials
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated:  1/5/2017
Katmai Oncology Group
mi
from
Anchorage, AK
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
Status: Enrolling
Updated: 1/5/2017
Katmai Oncology Group
mi
from
Anchorage, AK
Click here to add this to my saved trials